Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer
Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Welcome to APCCC 2021
ESMO 2021 Roundup
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma
OncoAlert and ecancer - ESMO 2021 Day 5
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation
Neoadjuvant chemotherapy with CapeOx alone vs standard chemoradiotherapy (CRT) with Capecitabine for patients with LARC
Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer
Novel therapies in multiple myeloma
OncoAlert and ecancer - ESMO 2021 Day 4